Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
SVF Endurance (Cayman) Ltd and affiliated reporting persons disclosed insider sales of 524,297 shares of Vir Biotechnology, Inc. (VIR) across two dates in early October 2025. The sales occurred on 10/03/2025 and 10/06/2025 at weighted average prices of approximately $5.5553 and $5.6878, respectively, and were executed under a Rule 10b5-1 trading plan established on 09/03/2025. Following these disposals the reporting group beneficially owned 16,159,744 shares.
The filing clarifies that SVF Endurance (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited appointed as the alternative investment fund manager responsible for investment decisions.
Vir Biotechnology, Inc. submitted a Form 144 notifying a proposed sale of 1668404 shares of its Common Stock through BTIG, LLC on the NASDAQ with an approximate aggregate market value of $9526586.84. The filing shows the shares were originally acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that had been purchased between August 2017 and January 2019, with 21666666 shares noted as the amount acquired and 01/31/2019 listed as a payment date. The issuer's total shares outstanding are listed as 138916426, and the proposed approximate sale date is 10/03/2025. The filer represents there are no undisclosed material adverse facts and indicates no securities were sold by this person in the past three months.
Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $5.8362 per share, with individual sale prices ranging from $5.68 to $5.99. After the reported disposition, the filing shows the reporting person beneficially owned 1,232,391 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and includes an undertaking to provide detailed per-price sale breakdowns on request.
Form 144 notice for Vir Biotechnology, Inc. (VIR) shows a proposed sale of 66,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $376,860.00, targeting an approximate sale date of 10/01/2025 on NASDAQ. The shares were originally acquired as pre-IPO stock from the issuer on 01/17/2017. The filer has completed prior Rule 10b5-1 plan sales of 22,000 shares on 09/02/2025 for $109,810.80 and 22,000 shares on 08/01/2025 for $109,698.60. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references a trading plan date field if relying on Rule 10b5-1.
Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares on 09/02/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $4.9914, with individual sale prices ranging from $4.88 to $5.07. After the reported sales, the filing shows 1,254,391 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and discloses that full breakdowns of shares sold at each price are available upon request.
Vir Biotechnology (VIR) filed an 8-K to disclose a material R&D milestone. On 24 Jul 2025 the company dosed the first patient in a Phase 1 trial of VIR-5525, an investigational dual-masked T-cell engager that targets EGFR-expressing tumors. Management reported the event under Item 8.01 and attached the related press release as Exhibit 99.1. No financial results, guidance or partnering details were included.
The dosing signals the formal clinical start of VIR-5525 and expands VIR’s oncology pipeline beyond its infectious-disease franchise. While the filing does not quantify trial size, endpoints or timelines, Phase 1 initiation is typically a prerequisite for value-creating data read-outs and potential future partnerships. Investors should note, however, that first-in-human studies are high-risk and non-revenue-generating at this stage.